MP R Weekly Dose 138 — Elahere Gets Accelerated Approval; Zejula Use Restricted; Update for IUD System; Interchangeable Insulin Products; Panel Votes on Tenapanor

<p><span style="font-weight: 400;">Newly approved gynecologic cancer treatment; Zejula has it’s use restricted; intrauterine system use extended; a second insulin product is approved as a biosimilar to Lantus; and an FDA Advisory Committee take a vote on tenapanor.</span></p>